Hottub News

Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine

3 reports from 3 outlets in 1 language · first reported · updated · JSON

HealthScience & technologyF. Hoffmann-La Roche LtdRocheThe New England Journal of MedicineGenentechGiredestrant

Reports

  1. F. Hoffmann-La Roche Ltd: Roche's giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicinefinanznachrichten.de · en ·
  2. Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicinetimesargus.com · en ·
  3. Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of MedicineGlobeNewswire — public companies · en ·

More in Health

  1. Former Eljamel patient’s ‘shock’ at health board’s approach to inquiry131 outlets
  2. Democratic Republic of Congo: More than 4,000 people in the DR Congo have died from Ebola93 outlets
  3. More than 4000 Ebola deaths in Democratic Republic of Congo59 outlets
  4. On ventilator and unconscious, what's next for Christa Pike after surviving lethal injection61 outlets
  5. Here's why experts say now is an ideal time to protect yourself from flu43 outlets
  6. Life expectancy almost back to pre-Covid levels, says WHO36 outlets